

DELPHION

No acti

Select CR

RESEARCH**PRODUCTS****INSIDE DELPHION**[Log Out](#) [Work Files](#) [Saved Searches](#)[My Account](#)Search: [Quick/Number](#) [Boolean](#) [Advanced](#)**Derwent Record**View: [Expand Details](#) Go to: [Delphion Integrated View](#)Tools: [Add to Work File](#): [Create new](#)

Derwent Title: **Vitamin D derivative formulation showing good skin penetration useful for treatment of skin disorders, especially psoriasis comprising active agent, volatile silicone and non-polar, non-volatile phase in vehicle**

Original Title: ☒ **FR2862540A1: COMPOSITION SOUS FORME DE SPRAY COMPRENANT UN ACTIF PHARMACEUTIQUE, AU MOINS UN SILICONE VOLATILE ET UNE PHASE NON POLAIRE NON VOLATILE**

Assignee: **GALDERMA RES & DEV SNC** Standard company
Other publications from [GALDERMA RES & DEV SNC \(CIRD\)](#)...

Inventor: **FREDON L; MALLARD C; PITRE F;**

Accession/Update: **2005-374532 / 200543**

IPC Code: **A61K 31/59 ; A61K 9/12 ; A61K 47/02 ; A61P 9/00 ; A61P 17/00 ; A61P 19/00 ; A61P 35/00 ; A61P 37/00 ;**

Derwent Classes: **A96; B07; D21; A26; B01; B05;**

Manual Codes: **A06-A00E3**(Inorganic silicon polymers use as medical, dental, cosmetic and veterinary) , **A12-V01**(Medicines, pharmaceuticals) , **B03-G(D** (calciferol)) , **B04-B01C3** (Mineral oils and waxes) , **B04-C03F**(Silicones) , **B05-B01B**(Si organic) , **B10-E04B**(Alcohols containing carbocyclic ring(s)) , **B10-E04D**(Other alcohols) , **B12-M01A**(Aerosol) , **B12-M12B**(External, topical) , **B14-A01** (Antibacterial [general]) , **B14-B08**(Antilichen) , **B14-C06** (Antirheumatic) , **B14-E12**(Anorectic, obesity treatment (appetite depressant)) , **B14-F01**(Cardioactive general and other) , **B14-F02**(Circulatory active general and other) , **B14-F06**(Antilipaemic) , **B14-F07** (Antiartherosclerotic) , **B14-G03**(Immunomodulatory) , **B14-H01**(Anticancer general and other) , **B14-K01** (Respiratory active general and other) , **B14-N06B** (Periodontal) , **B14-R01**(Cosmetic general and other) , **B14-R02**(Hair preparation) , **B14-S01**(Multiple sclerosis treatment, demyelinating diseases) , **B14-S04**(Diabetes (general)) , **B14-S16**(Many diseases treated (15 or over, claimed/disclosed)) , **D08-B03A**(Products for promoting growth) , **D08-B09A**(Cosmetic preparations for skin care)

Derwent Abstract: ([FR2862540A](#)) **Novelty** - In a composition (A) consisting of a pharmaceutical vehicle containing an active agent (I), volatile silicone(s) (II) and a non-polar, non-volatile phase (III), the active agent (I) is a vitamin D derivative.
Detailed Description - An INDEPENDENT CLAIM is also included for a method for improving the penetration of a vitamin D derivative active agent, involving applying a composition (A) to the skin in the form of a spray.
ACTIVITY - Dermatological; Antiseborrheic; Antiinflammatory; Antiallergic; Immunosuppressive; Antipsoriatic; Antirheumatic; Cytostatic; Virucide; Vulnerary; Anorectic; Antilipemic; Antidiabetic; Antiarthritic; Endocrine-Gen.; Antiasthmatic; Neuroprotective; Cardiant; Antiartherosclerotic; Hypotensive.
MECHANISM OF ACTION - None given.
Use - Composition (A) is specifically used as a medicament for treating:
(1) dermatological conditions associated with keratinization disorders affecting

differentiation and proliferation, especially acne vulgaris, comedones, polymorphic acne, rosaceae, nodulokystic acne, acne conglobata, senile acne or secondary acne (e.g. solar, drug-induced or professional acne);
 (2) ichthyosis (or similar states), Darrier disease, palmoplantar keratoderma, leukoplasia (or similar states) or cutaneous or mucosa (buccal) lichen;
 (3) dermatological disorders with an inflammatory, immuno-allergic component (with or without cellular proliferation), especially cutaneous, mucosal or ungual psoriasis, psoriatic rheumatism, cutaneous atopy (e.g. eczema), respiratory atopy or gingival hypertrophy;
 (4) benign or malignant, dermal or epidermal proliferation of viral or other origin, especially common or planar verrucas, veruciform epidermodysplasia, oral or florid papillomatosis or T lymphoma;
 (5) UV-induced proliferation, especially baso- or spinocellular epithelioma;
 (6) precancerous cutaneous lesions, especially keratocanthoma;
 (7) immune dermatosis, especially lupus erythematosus;
 (8) bullous immune diseases;
 (9) collagen diseases, especially scleroderma;
 (10) dermatological or general disorders with an immunological component;
 (11) cutaneous disorders caused by exposure to UV radiation, chronological or light-induced skin aging, actinic keratosis and pigmentation or any disorders associated with chronological or light-induced aging, especially xerosis;
 (12) sebaceous function disorders, especially acne hyperseborrhea, simple seborrhea or seborrheic dermatitis;
 (13) cicatrization disorders or stretch marks;
 (14) pigmentation disorders, such as hyperpigmentation, melasma, hypopigmentation or vitiligo;
 (15) lipid metabolism disorders, such as obesity, hyperlipidemia, non-insulin dependent diabetes or syndrome X;
 (16) inflammatory disorders such as arthritis;
 (17) cancerous or pre-cancerous states;
 (18) alopecia, especially due to chemotherapy or radiation;
 (19) immunological disorders, such as asthma, type I diabetes mellitus, plaque sclerosis or other types of selective immunological dysfunction; or
 (20) cardiovascular disorders such as arteriosclerosis or hypertension (all claimed).

In particular the use of (A) for treating psoriasis is claimed. More generally (A) is useful in dermatological and cosmetic applications.

Advantage - Composition (A) provides good penetration of the active agent (I), and is well accepted and tolerated by patients. In particular (A) provides good skin penetration in the absence of (potentially irritating) glycol pro-penetrants.

Dwg.0/0

Family:

PDF	Patent	Pub. Date	Derwent Update	Pages	Language	IPC Code
<input checked="" type="checkbox"/>	FR2862540A1	* 2005-05-27	200539	28	French	A61K 31/59
Local appls.: FR2003000013660 Filed:2003-11-21 (2003FR-0013660)						

INPADOC
Legal Status:

None

Priority Number:

Application Number	Filed	Original Title
FR2003000013660	2003-11-21	COMPOSITION SOUS FORME DE SPRAY COMPRENANT UN ACTIF PHARMACEUTIQUE, AU MOINS UN SILICONE VOLATILE ET UNE PHASE NON POLAIRE NON VOLATILE

Chemical
Indexing Codes:

[Show chemical indexing codes](#)

Ring Index

[Show ring index numbers](#)

Numbers:
 ☞ Extended [Show extended polymer index](#)
 Polymer Index:
 ☞ Specific [Show specific compounds](#)
 Compound
 Numbers:
 ☞ Registry 19[M2]:0245U
 Numbers:
 ☞ Unlinked 0245U
 Registry Numbers:
 ☞ Related
 Accessions:

Accession Number	Type	Derwent Update	Derwent Title
C2005-116387	C		
2005-425254	R	200543	Sprayable composition useful for producing medicinal product for treating e.g. rosacea comprises active agent derived from vitamin D, volatile silicone, nonvolatile